Kelly R. Pitts

Biography

Dr. Pitts joined Corgenix in 2011.  Prior to arriving at Corgenix, Dr. Pitts was the Global Group Leader for the Global Bioassay Group tasked with developing and maintaining both commercial and development potency methods at Amgen, Inc.  While at Gilead Sciences, Inc. and Myogen, Inc., Dr. Pitts led the Molecular Pharmacology department, where his group developed cell- and tissue-based methods for determining drug candidate mechanism of action in cardiovascular, pulmonary, renal, and hepatic therapeutic areas.  Dr. Pitts has extensive experience in developing biomarker-driven assays to support discovery research, clinical development, and commercialization of small-molecule and biologic-based drugs.  He continues to maintain a broad interest in clinical biomarkers, detection technologies, and drug pharmacology, and has published several peer-reviewed manuscripts in these fields. Pitts holds a Bachelors of Science degree from Brigham Young University and a Doctorate degree from Mayo Graduate School, Mayo Clinic (Rochester).  Dr. Pitts is a current associate editor for the Journal of Pharmacological and Toxicological Methods, and is a former appointed Chair of the Physiologists in Industry Committee of the American Physiological Society. He is also a registered Patent Agent with the United States Patent and Trademark Office

Research Interest

Clinical biomarkers, detection technologies, and drug pharmacology